Potential new antifungal agents

Current Opinion in Infectious Diseases

Volumn 10, Issue 6, 1997, Pages 449-458

  Groll, Andreas H ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; 2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; AMPHOTERICIN B; ANTIFUNGAL AGENT; BENANOMICIN A; CECROPIN A; CILOFUNGIN; CYTOKINE; ECHINOCANDIN B DERIVATIVE; ENZYME INHIBITOR; GENACONAZOLE; LIPOSOME; NATURAL PRODUCT; NIKKOMYCIN Z; NYSTATIN; PNEUMOCANDIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PRADIMICIN A; RECOMBINANT PROTEIN; TRIAZOLE DERIVATIVE; VACCINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; CLINICAL TRIAL; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; FUNGICIDAL ACTIVITY; HUMAN; IMMUNOMODULATION; MYCOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; VACCINE PRODUCTION;

EID: 0030733419     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199712000-00007     Document Type: Review

References (129)

1. Janknegt R, vanEtten EWM, de Marie S: Lipid formulations of amphotericin B. Curr Opin Infect Dis 1996, 9:403-406. A brief review of the lipid formulations of amphotericin B and their clinical indications.
2. Hiemenz JW, Walsh TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996, 22(suppl. 2): S133-144. An in-depth review of the lipid formulations of amphotericin B and their clinical indications.
3. Richardson K, Bell AS, Dickinson RP, Naryanashwami S, Ray SJ: UK 109496, a novel wide spectrum triazole derivative for the treatment of fungal infections: synthesis and SAR. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:125.
4. Troke PF, Bell AS, Dickinson RP, Hitchcock CA, Jezequel S, Naryanashwami S, Ray SJ, Richarson K: UK 109496, a novel wide spectrum triazole derivative for the treatment of systemic fungal infections: discovery and antifungal properties. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:125.
5. Barchiesi F, Restrepo M, McGough DA, Rinaldi MG: In vitro activity of a new antifungal triazole, UK 109496. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:125.
6. Barry AL, Brown SD: In-vitro studies of two triazole antifungal agents (voriconazole UK 109496 and fluconazole) against Candida species. Antimicrob Agents Chemother 1996, 40:1948-1949.
7. Espinel-Ingroff A, Flynn T: Antifungal activity of the new triazole voriconazole against established, new and emerging yeast pathogens: a comparative study. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:114.
8. Hitchcock CA, Pye GW, Oliver GP, Troke PF: UK 109946, a novel wide spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:125.
9. Ruhnke M, Schmidt-Westhausen A, Trautmann M: In-vitro activities of voriconazole (UK 109496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997, 41:575-577.
10. Espinel-Ingroff A: Evaluation of the in-vitro activity of the new triazole voriconazole against opportunistic filamentous fungi. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:114.
11. McGinnis MR, Pasarell L, Cooper CR: In vitro susceptibility of clinical mould isolates to UK 109,496 In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:99.
12. Murphy M, Bernard EM, Ishimaru T, Armstrong D: Activity of voriconazole (UK-109496) against clinical isolates of Asperigillus species and its effectiveness in an experimental model of invasive pulmonary asperigillosis. Antimicrob Agents Chemother 1997, 41:696-698.
13. Oakley KL, Moore CB, Denning DW: In vitro activity of voriconazole against Aspergillus spp. and comparison with amphotericin B and itraconazole. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:114.
14. Radford SA, Johnson EM, Warnock DW: In vitro studies of activity of voriconazole (UK 109,496), a new triazole antifungal agent, against emerging and less common mold pathogens. Antimicrob Agents Chemother 1997, 41:841-843.
15. Sutton DA, Fothergill AW, Barchiesi FJ, Rinaldi MG: In vitro activity of voriconazole against dimorphic fungi. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:114.
16. Hitchcock CA, Andrews RJ, Lewis BGH, Troke PF: UK 109946, a novel wide spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Asperigillus. In Abstracts of the 35th Interscience Conference on Anitmicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:125.
17. George D, Miniter P, Andriole VT: Efficacy of UK 109496, a new azole antifungal agent, in an experimental model of invasive asperigillosis. Antimicrob Agents Chemother 1996, 40:86-91.
18. Martin MV, Yates J, Hitchcock CA: Comparison of voriconazole (UK 109,946) and itraconazole in the prevention of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997, 41:13-16.
19. Hitchcock CA, Andrews RJ, Lewis BGH, Troke PF: UK 109946, a novel wide spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Cryptococcus In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:125.
20. Patterson BE, Coates PE: UK 109946, a novel wide spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:126.
21. Jezequel SG, Clark M, Evans K, Roffey S, Wastall P, Webster R: UK 109946, a novel wide spectrum triazole derivative for the treatment of fungal infections: disposition in animals. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:126.
22. Patterson BE, Roffey S, Jezequel SG, Jones B: UK 109946, a novel wide spectrum triazole derivative for the treatment of fungal infections: disposition in man. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995.
23. Troke PF, Brammer KW, Hitchcock CA, Yonren S, Sarantis N: UK 109946, a novel wide spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC). In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:125.
24. Denning D, DelFavero A, Gluckman E, Norfolk D, Ruhnke M, Yonren S, Troke P, Sarantis N: UK 109946, a novel wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive asperigillosis. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:126.
25. Dupont B, Denning D, Lode H, Yonren S, Troke P, Sarantis N: UK 109,946, a novel wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive asperigillosis. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:127.
26. Girijavallabhan VM, Saksena AK, Lovey RG, Bennet F, Pike RE, Wang H, Pinto P, Liu YT, Patel N, Ganguly AK: Sch 56592, a novel orally active broad spectrum antifungal agent. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:123.
27. Saksena AK, Girijavallabhan VM, Lovey RG, Bennet F, Pike RE, Wang H, Pinto P, Liu YT, Patel N, Ganguly AK: Novel analogues of Sch 51048: synthesis and preliminary structure activity relationships. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:127.
28. Galgiani JN, Lewis ML: In vitro studies of activities of the antifungal triazoles Sch 56692 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother 1997, 41:180-183.
29. Law D, Denning DW: In vitro activity of Schering 56592 compared with fluconazole and itraconazole against Candida spp. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:115.
30. Parmegiani R, Cacciapuoti A, Loebenberg D, Antonacci B, Norris C, Yarosh-Tomaine T, Michalski M, Hare RS, Miller GH: In vitro activity of Sch 56952, a new antifungal agent. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:123.
31. Pfaller MA, Messer S, Jones RN: Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997, 41:233-235.
32. Perfect JR, Cox GM, Dodge RK, Schell WA: In vitro and in vivo efficacies of the azole Sch 56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996, 40:1910-1913.
33. Dupont B, Improvisi L, Dromer F: In vitro and in vivo activity of a new antifungal agent Sch 56592. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:116.
34. Fothergill AW, Sutton DA, Rinaldi MG: In vitro head-to-head comparison of Schering 56592, amphotericin B, fluconazole and itraconazole against a spectrum of filamentous fungi. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:115.
35. Oakley KL, Moore CB, Denning DW: In vitro activity of Sch 56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997 41:1124-1126.
36. Sugar AM, Liu XP: In vitro and in vivo activities of Sch 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996, 40:1314-1316.
37. Cacciapuoti A, Parmegiani R, Loebenberg D, Antonacci B, Moss LE, Menzel F, Norris C, Hare RS, Miller GH: Efficacy of Sch 56592 in pulmonary aspergillosis and candidiasis in mice. In Abstracts of the 35th Interscience Conference on Anitmicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:124.
38. Cacciapuoti A, Loebenberg D, Frank D, Moss EL, Menzel F, Michalski M, Norris C, Yaremko B, Hare RS, Miller GH: Effect of delayed or extended treatment with Sch 56592 or concomittant treatment with amphotericin B in murine models of pulmonary aspergillosis and systemic candidiasis. In Abstracts of the 36th Interscience Conference on Anitmicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:116.
39. Cole GT, Seshan KR, Loebenberg D: Evaluation of Sch 56592 in clearance of GI mucosal candidasis from mice with retroviral-induced immunodeficiency. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:116.
40. Parmengiani R, Cacciapuoti A, Loebenberg D, Antonacci B, Norris C, Yaroh-Tomaine T, Michalski M, Hare RS, Miller GH: Efficacy of Sch 56592 in topical infection models. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:124.
41. Graybill J, Najvar L, Bocanegra R, Fothergil A, Luther M: Treatment of murine pulmonary aspergillosis with Sch 56592. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:117.
42. Oakley KL, Morrissey G, Denning DW: Efficacy of Sch 56592 in two immunocompromised murine models of invasive aspergillosis. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:116.
43. Patterson TF, Kirkpatrick WR, McAtte RK, Loebenberg D: Efficacy of Sch 56592 in a rabbit model of invasive aspergillosis. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:116.
44. Wheat J, Bick C, Connolly P, Smedema M, Durkin M, Kohler S, Loebenberg D: Comparison of a new triazole, Schering 56592, with itraconazole and amphotericin B for treatment of murine histoplasmosis. In Abstracts of the 36fh Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:117.
45. Lutz JE, Clemons KV, Stevens DA: Efficacy of Sch 56592 in a murine model of systemic coccidioidomycosis In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:117.
46. Urbina JA, Payares G, Sonoja C, Contreras LM, Liendo A, Piras MM, Piras R: In vitro and in vivo antiproliferative effects of Sch 56592 against Trypanosoma cruzi, the causative agent of Chagas disease. In Abstracts of the 36th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:117.
47. Nomeir A, Kumari P, Hilbert MJ, Loebenberg D, Cacciapuoti A, Menzel F, Moss E, Hare R, Miller GH, Cayen MN, Lin C: Comparative pharmacokinetics of a new triazole antifungal agent Sch 56592 in mice, rats, rabbits, dogs and Cynomolgus monkeys. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:124.
48. Nomeir AA, Kumari P, Loebenberg D, Cacciapuoti A, Hare R, Miller G, Sangekar S, Mahashabde S, Vadino WA, Lee PL, Lin CC, Cayen MM: Bioavailability of Sch 56592, a broad spectrum triazole antifungal agent from various formulations. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:117.
49. Hata K, Kimura J, Miki H, Toyosawa T, Nakamura T, Katsu K: In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 1996, 40:2237-2242.
50. Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K: Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1996, 40:2243-2247.
51. Nakamura S, Sakai R, Sonoda J, Katoh T, Kaneko T, Horie T: ER-30346, a novel antifungal triazole: IV. Pharmacokinetic and toxicological studies in mice, rats, and dogs. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:129.
52. Bartoli J, Turmo E, Belloc J, Alguero M, Boncompte E, Vericat L, Garcia-Raffanell J, Forn J: UR-9746 and UR-9751: two new azole derivatives with potent oral antifungal activity. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:127.
53. Bornay-Llinares FJ, Torres-Rodriguez JM: Anticryptococcal activity of a new azole derivative (UR-9746) in a murine model. In Abstracts of the 35th Interscience Conference on Antimicrobiol Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:128.
54. Clemons KV, Stevens DA: Efficacies of two novel azole derivatives each containing a morpholine ring, UR-9746 and UR-9751, against systemic murine coccidiodomycosis. Antimicrob Agents Chemother 1997, 41:200-203.
55. Restrepo M, Najvar L, Barchiesi F, Graybill JR: Treatment of murine cryptococcal meningitis with UR 9751 and UR 9756. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:128.
56. Stevens DA, Devine DJ, Martinez M, Aristizabal B: In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:127.
57. Yotsuji A, Shimizu K, Araki K, Fujimaki K, Nishida N, Hori R, Annen N, Yamamoto S, Hayakawa H, Imaizumi H, Watanabe Y, Narita H: T-8581, a new orally and parenterally active triazole antifungal: in vitro and in vivo evaluation. Antimicrob Agents Chemother 1997, 41:30-34.
58. Debono M, Gordee RS: Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994, 48:471-497.
59. Angiolella L, Facchin M, Stringaro A, Maras B, Simonetti N, Cassone A: Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics. J Infect Dis 1996, 173:684-690.
60. Hector RF: Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993, 6:1-21.
61. Bartlett MS, Current WL, Goheen MP, Boylan CJ, Lee CH, Shaw MM, Queener SF, Smith JW: Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 1996, 40:1811-1916.
62. Current WL, Boylan CJ, Raab PP: Anti-Pneumocystis activity of LY 303366 and other echinocandin B analogues. In Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC:American Society for Microbiology; 1993:186.
63. Gordee R, Farmer J, Flokowitsch J, Haeber P: In vitro antifungal activity of LY 303366, a new antifungal agent derived from echinocandin B. In Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1993:185.
64. Pfaller MA, Messer S, Coffman S: In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY 303366, and other antifungal agents. Antimicrob Agents Chemother 1997, 41:763-766.
65. Rennie R, Sand C, Smith S: In vitro activity of antifungal agent LY 30336 against Candida species, other yeasts and Aspergillus species. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:107.
66. Stevens DA, Martinez M, Devine MJ: Antifungal activity of LY 303366, an echinocandin beta glucan synthase inhibitor In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:107.
67. Tang J, Parr TJ, Turner W, Debono M, Landgrandeur L, Burkhard F, Rodriquez M, Zweifel M, Nissen J, Clingerman K: LY 303366: a noncompetitive inhibitor of (1,3)-beta-D-Glucan synthases from Candida albicans and Aspergillus fumigatus. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:186.
68. Uzun O, Kocagoez S, Cetinkaya Y, Arikan S, Uenal S: In vitro activity of a new echinocandin, LY 303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother 1997, 41:1156-1157.
69. Zeckner D, Butler T, Boylan C, Boyll B, Watson P, Current W: In vitro evaluation of LY 303366 against Candida species clinical isolates and evaluation of efficacy in a murine model of systemic candidasis. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:130.
70. Zhanel GC, Karlowsky JA, Harding GAJ, Balko TV, Zelenitsky SA, Friesen M, Kabani A, Turik M, Hoban DJ: In vitro activity of a new semisynthetic echinocandin, LY 303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatidis, and Aspergillus species. Antimicrob Agents Chemother 1997, 41:863-865.
71. Friesen M, Harding G, Karlowsky J, Balko T, Hoban T, Kabani A, Zelenitski S, Turik M, Zhanel GG: Antifungal pharmacodynamic activity of the investigational echinocandin LY 303366 against fluconazole sensitive and fluconazole resistant Candida albicans. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:108.
72. Raab P, Zeckner D, Boyll B, Boylan C, Current W: LY 303366: comparison of activity in murine models of Aspergillus fumigatus infection. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1994:252.
73. Zeckner D, Butler T, Boylan C, Boyll B, Lin Y, Raab P, Schmidtke J, Current W: LY 303366 activity against systemic aspergillosis and histoplasmosis in murine models. In Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1993:186.
74. Zeckner D, Butler T, Boylan C, Boyll B, Raab P, Current W: LY 303366 activity in a rat mucocutaneous vaginal candidiasis model. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1994:252.
75. Zeckner D, Butler T, Boylan C, Boyll B, Lin Y, Raab P, Schmitdke J, Current W: LY 303366 activity in a murine systemic candidiasis model. In Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1993:186.
76. Lukas R, Desante K, Hatcher B, Hemingway J, Lachno R, Brooks S, Turik M: LY 303366 single dose pharmacokinetics and safety in healthy male volunteers. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:108.
77. Bartizal K, Flattery A, Lynch L, Pacholok C, Gill CJ, Rosen H, Scott P, Kropp H: In vitro preclinical evaluation studies with the pneumocandin antifungal L 743872. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC:American Society for Microbiology; 1996:105.
78. Espinel-Ingroff A: In vitro studies with L 743872, a water soluble pneumocandin: a comparative study. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:105.
79. Fothergill AW, Sutton DA, Rinaldi MG: Antifungal susceptibility testing of Merck L 743872 against a broad range of fungi. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology; 1996:105.
80. Nelson PW, Lozano-Chiu M, Rex JH: In vitro activity of L 743872 against putatively amphotericin B and fluconazole resistant Candida isolates. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology; 1996:104.
81. Vasquez JA, Boikov D, Lynch ME, Sobel JD: In vitro antifungal activity of L 743872, a new pneumocandin, against sensitive and resistant Torulopsis and Candida species. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: Society for Microbiology; 1996:105.
82. Chin NX, Weitzman I, Della-Latta P: A study of in vitro antifungal activity of L 743872 against Fusarium, Rhizopus and Trichosporon species. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:105.
83. DelPoeta M, Schell WA, Perfect JR: In vitro antifungal activity of L 743872 against a variety of molds. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:105.
84. Franzot SP, Casadevall A: Pneumocandin L 743872 enhances the activity of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997, 41:331-336.
85. Abbruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VP, Kropp H, Rosen H, Bartizal K: Evaluation of water soluble pneumocandin L 743872 in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:106.
86. Bernard EM, Ishimaru T, Armstrong D: Low doses of pneumocandin L 743872 are effective for prevention and treatment in an animal model of pulmonary aspergillosis. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:106.
87. Flattery AM, Abruzzo GK, Gill CJ, Smith JG, Bartizal K: New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents. Antimicrob Agents Chemother 1996, 40:1604-1609.
88. Najvar L, Fothergill A, Luther M, Graybill J: Efficacy of L 743872 in murine disseminated candidiasis. In Abstracts of the 33th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:106.
89. Smith JG, Abruzzo GK, Gill CJ, Flattery AM, Kong L, Rosen H, Kropp H, Bartizal K: Evaluation of pneumocandin L 743872 in neutropenic mouse models of diseminated candidiasis and aspergillosis. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:107.
90. Powles MA, Anderson J, Liberator P, Schmatz DM: Efficacy of semisynthetic pneumocandin analog L 743872 against Pneumocystis carinii in murine models. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC American Society for Microbiology; 1996:107.
91. Najvar L, Graybill J, Montalbo E, Barchiesi F, Luther M: Evaluation of L 743872 in the treatment of murine histoplasmosis. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:107.
92. Hajdu R, Pelak B, Sundelof J, Thompson R, Rosen H, Kropp H: Pharmacokinetics of L 742872 in the mouse, rat, Rhesus and Chimpanzee. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:107.
93. Oki K, Konishi M, Tomatsu K, Tomita K, Saitoh K: Pradimicin, a novel class of potent antifungal antibiotics. J Antibiot 1988, 41:1701-1704.
94. Takeuchi T, Hara T, Naganawa H, Okada M, Hamada M, Umezawa H, Gomi S, Sezaki M, Kondo S: New antifungal antibiotics, benanomicins A and B from an Actinomycete. J Antibiot 1988, 41:807-811.
95. Walsh TJ, Giri N: Pradimicins: a novel class of broad-spectrum antifungal compounds. Eur J Clin Microbiol Infect Dis 1997, 16:93-97. An introduction to the pradimicin family of antibiotics.
96. Sawada Y, Numata K, Murakami T, Tanimichi H, Yamamoto S, Oki T: Calcium-dependent anticandidal action of pradimicin A. J Antibiot (Tokyo) 1990, 43:715-721.
97. Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE: In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob Agents Chemother 1995, 39:295-300.
98. Wardle HM, Law D, Denning DW: In vitro activity of BMS-181184 compared with those of fluconzole and amphotericin B against various Candida spp. Antimicrob Agents Chemother 1996, 40:2229-2231.
99. Watanabe M, Hiratani T, Uchida K, Ohtsuka K, Watabe H, Inouye S, Kondo S, Takeuchi T, Yamaguchi H: The in-vitro activity of an antifungal antibiotic benanomicin A in comparison with amphotericin B. J Antimicrob Chemother 1996, 38:1073-1077.
100. Gonzales CE, Shetty D, Giri N, Love W, Klygis K, Lyman C, Bacher J, Walsh TJ: Efficacy of pradimicin against disseminated candidiasis. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology; 1996:131.
101. Gonzalez CE, Shetty D, Giri N, Love W, Kligys K, Sein T, Lyman C, Bacher J, Walsh TJ: Efficacy of pradimicin against invasive pulmonary aspergillosis. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:131.
102. Patterson TF, Kirkpatrick WR, McAtee RK: The activity of pradimicin (BMS-181184) in experimental invasive aspergillosis. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:31.
103. Ohtsuka K, Watanabe M, Orikasa Y, Inouye S, Uchida K, Yamaguchi H, Kondo S, Takeuchi T: The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole. J Antimicrob Chemother 1997, 39:71-77.
104. Yasuoka A, Oka S, Komuro K: Successful treatment of Pneumocystis carinii pneumonia in mice with benanomicin A (ME1451). Antimicrob Agents Chemother 1995, 39:720-724.
105. Hamilton-Miller JMT: Fungal sterols and the mode of action of the polyene antibiotics. Adv Appl Microbiol 1974, 17:109-134.
106. Mehta RT, Hopfer RL, Gunner LA, Juliano RL, Lopez-Berestein G: Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother 1987, 31:1897-1900.
107. Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G: Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 1987, 31:1901-1903.
108. Gonzalez CE, Giri N, Shetty D, Kligys K, Love W, Sein T, Walsh TJ: Efficacy of a lipid formulation of nystatin against invasive pulmonary aspergillosis. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:21.
109. Wallace TL, Paetznick V, Cossum PA, Anaissie E: Nyotran (liposomal nystatin) activity against disseminated aspergillus fumigatus in neutropenic mice. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:31.
110. Boutati EI, Maltezou HC, Lopez-Berestein G, Vartivarian SE, Anaissie EJ: Phase-I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia in patients with hematological malignancies. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:330.
111. Cossum PA, Wyse J, Simmons V, Wallace TL, Rios A: Pharmacokinetics of nyotran (liposomal nystatin) in human patients. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:17.
112. Dahn U, Hagenmaier H, Hohne H, Konig WA, Wolf G, Zahner H: Stoffwechselprodukte von Mikroorganismen. 154. Mitteilung. Nikkomycin, ein neuer Hemmstoff der Chitinsynthese bei Pilzen. Arch Microbiol 1976, 19:143-160.
113. Hector RF, Zimmer BL, Pappagianis D: Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother 1990, 34:587-593.
114. Flores ME, Hector RF: In vitro activity of the antifungal nikkomycin Z (SP-920704) in combination with fluconazole or itraconazole vs. yeasts. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:133.
115. Hector RF, Braun PC: Synergistic action of nikkomycins X and Z with papulacandin B on whole cells and regenerating protoplasts of Candida albicans. Antimicrob Agents Chemother 1986, 29:389-394.
116. Hector RF, Schaller K: Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 1992, 36:1284-1289.
117. Li RK, Fothergil AW, Rinaldi MG: In vitro antifungal activity of SP-920704 in combination with fluconazole and itraconazole. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:132.
118. Milewski S, Mignini F, Borowski E: Synergistic action of nikkomycin X/Z with azole antifungals on Candida albicans. J Gen Microbiol 1991, 137:2155-2161.
119. Pfaller M, Gordee R, Gerarden T, Yu M, Wenzel R: Fungicidal activity of cilofungin (LY121019) alone and in combination with anticapsin or other antifungal agents. Eur J Clin Microbiol Infect Dis 1989, 8:564-567.
120. Clemons KV, Stevens DA: Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1994:50.
121. Georgopapadakou NH, Walsh TJ: Antifungal agents: chemotherapeutic targets and immunologie strategies. Antimicrob Agents Chemother 1996, 40:279-291. A comprehensive review with focus on potential targets for antifungal drug design and the evolving field of potential immunological interventions.
122. Perfect JR: Fungal virulence genes as targets for antifungal chemotherapy. Antimicrob Agents Chemother 1996, 40:1577-1583. A worthwhile discussion of virulence genes as potential targets for antifungal treatment.
123. Hancock RE: Peptide antibiotics. Lancet 1997, 349:418-422. An introduction to the realm of naturally occurring cationic peptides as candidates for antimicrobial treatment.
124. DeLucca AJ, Bland JM, Jacks TJ, Grimm C, Cleveland TE, Walsh TJ: Fungicidal activity of cecropin A. Antimicrob Agents Chemother 1997, 41:481-483.
125. Ahmad I, Perkins WR, Lupan DM, Selsted ME, Janoff AS: Liposomal entrapment of the neutrophil derived peptide indolicidin endows it with in vivo antifungal activity. Biochim Biophys Acta 1995, 26:109-114.
126. Lim E, Wong P, Fadem M, Motchnick P, Bakalisnky M, Little R: Fungicidal activity of synthetic peptides derived from bactericidal/ permeability increasing protein (BPI). In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:132.
127. Horwitz AH, Little R, Fadem M, Motchnick P, Nadell R: Fungicidal peptides from bactericidal/permeability increasing protein (BPI) act synergistically with fluconazole on Candida albicans. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:132.
128. Appenzeller L, Lim E, Wong P, Fadem M, Motchnik P, Bakalinsky M, Little R: In vivo fungicidal activity of optimized domain III peptides derived from bactericidal/permeability increasing protein (BPI). In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:132.
129. O'Connell BC, Xu T, Walsh TJ, Sein T, Mastrangeli A, Crystal AR, Oppenheim FG, Baum BJ: Transfer of a gene encoding the anticandidal protein histatin 3 to salivary glands. Hum Gene Ther 1996, 7:2255-2261.